Ocugen, Inc.

OCGN

US67577C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:55:42 12/03/2026 pm IST			5-day change	1st Jan Change
2.315 ^USD	+0.65%		+30.47%	+68.16%

11/03	Top Midday Gainers	MT
11/03	Oppenheimer Initiates Ocugen at Outperform With $10 Price Target	MT

Ocugen Names Rita Johnson-Greene as CFO

Published on 02/09/2026 at 06:14 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Ocugen, Inc.

11/03	Top Midday Gainers	MT
11/03	Oppenheimer Initiates Ocugen at Outperform With $10 Price Target	MT
09/03	312,319,623 Common Stock of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.	CI
09/03	Certain Warrants of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.	CI
09/03	Certain Performance Stock Units of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.	CI
09/03	Certain Restricted Stock Units. of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026.	CI
04/03	Ocugen, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
04/03	Ocugen, Inc., Q4 2025 Earnings Call, Mar 04, 2026
04/03	Ocugen, Inc. Auditor Raises 'Going Concern' Doubt	CI
02/03	Ocugen Announces Phase 3 Limelight Enrollment Completion for Ocu400, A Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa	CI
09/02	Ocugen, Inc. Announces Executive Changes, Effective February 9, 2026	CI
09/02	Ocugen Names Rita Johnson-Greene as CFO	MT
09/02	Ocugen appoints Rita Johnson-Greene to chief financial officer	RE
09/02	Ocugen, Inc. Appoints Rita Johnson-Greene as Chief Financial Officer	CI
23/01	Ocugen Closes $20.9 Million Registered Direct Offering	MT

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Employees

116

Sector

Biotechnology & Medical Research

More about the company